Monopteros Therapeutics
www.monopterostx.comMonopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.
Read more
Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.
Read more
Country
State
Massachusetts
City (Headquarters)
Boston
Industry
Employees
1-10
Founded
2019
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive Officer
Email ****** @****.comPhone (***) ****-****
Reach decision makers at Monopteros Therapeutics
Free credits every month!
Monopteros Therapeutics FAQ
Boston, United States
Biotechnology Research
